Emerging HIV Therapies: The Evidence

Volume 8, Issue 3

Emerging HIV Therapies: The Evidence

In this issue:

Results from recent studies of two first-in-class antiretrovirals, as well as preliminary results of broadly neutralizing antibody therapies, may expand the possibilities in this new era of long-acting HIV prevention and treatment. What do the clinical trial data show? Which patients will most likely benefit should these new agents become widely available? What do clinicians need to know now to be best prepared for these emerging therapeutic options?

Those are some of the questions discussed by our guest authors — Meredith Clement, MD and Lauren Richey MD, MPH, FIDSA — from the Section of Infectious Disease at Louisiana State University Health Sciences Center in New Orleans in this issue of eHIV Review.

Learning objectives:

Describe clinical trial data for emerging antiretroviral therapies as treatment and prevention options.
Assess strengths and limitations of broadly neutralizing antibodies for HIV treatment and prevention.

Authors:

Meredith E. Clement, MD

Assistant Professor, Section of Infectious Disease
Louisiana State University Health Sciences Center, New Orleans

Lauren Richey, MD, MPH, FIDSA

Associate Professor, Section of Infectious Disease
Louisiana State University Health Sciences Center, New Orleans

Guest Faculty Disclosures

Dr. Clement has disclosed membership on advisory committees or review panels, board membership, etc for ViiV Healthcare and Roche. She has received royalties or patent beneficiary from UpToDate, as well as grant or research support from ViiV Healthcare and Gilead Sciences, Inc.

Dr. Richey has indicated that she has no financial interests in or relationships with a commercial entity. 

Unlabeled/Unapproved Uses

Dr. Clement and Dr. Richey have indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products. 

Program Directors:

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland
(she/her/hers)

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California
(he/him/his)

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)

Guest Faculty Disclosures:

Dr. Richey has indicated that she has no financial interests in or relationships with a commercial entity. 

Unlabeled/Unapproved Uses:

Dr. Clement and Dr. Richey have indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products. 

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: March 29, 2023
Expiration date: March 28, 2025

Start Issue